Riaan becomes first patient to receive experimental Cockayne syndrome gene therapy

In New York, a 6-year-old boy named Riaan has become the first patient in the world to receive a pioneering experimental gene therapy for Cockayne syndrome. This rare neurodegenerative genetic disorder causes rapid aging, severe developmental issues, and premature death. Riaan's condition is caused by a malfunctioning CSA gene, which is essential for DNA repair.

Refusing to accept a prognosis that his life expectancy would not exceed five years, Riaan's parents, Erika Alpan and her husband Ritsi, founded the Riaan Research Initiative. They successfully raised $4 million through awareness campaigns and donor support. Working with scientists from UMass Chan Medical School, Weill Cornell, and other institutions, they developed a treatment that introduces a healthy copy of the CSA gene into the brain using an AAV9 vector.

After years of work and negotiations with the FDA, the clinical trial was approved. The parents faced significant ethical dilemmas when deciding whether to proceed, as the treatment had only shown positive results in neonatal mouse models and had never been tested in humans. The procedure involves high-risk elements, including surgical cranial opening and immunosuppression.